Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BGM0504 vs semaglutide in Chinese patients with type 2 diabetes mellitus inadequately controlled on metformin ± sulfonylurea
CTR20244493Phase 3Active
- Sponsor
- Borray New Creation Biopharmaceutical Technology
- Start
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BGM0504 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Borray New Creation Biopharmaceutical Technology. Primary endpoint: Change in HbA1c from baseline at week 32. Started Jan 2025; status: active.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244493.